NYSE:VRX - Valeant Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.40 -0.83 (-3.43 %)
(As of 11/18/2018 04:49 AM ET)
Previous Close$23.40
Today's Range$23.36 - $24.43
52-Week Range$10.94 - $27.79
Volume6.57 million shs
Average Volume6.36 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:VRX
Previous SymbolNYSE:BVF
CUSIPN/A
Phone514-744-6792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees20,700
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable

Valeant Pharmaceuticals (NYSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals' stock symbol?

Valeant Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals' earnings last quarter?

Valeant Pharmaceuticals (NYSE:VRX) posted its quarterly earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.48 by $0.08. The specialty pharmaceutical company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. The firm's quarterly revenue was down 11.4% on a year-over-year basis. During the same period last year, the business posted $2.14 EPS. View Valeant Pharmaceuticals' Earnings History.

What price target have analysts set for VRX?

15 brokerages have issued 1-year price objectives for Valeant Pharmaceuticals' shares. Their forecasts range from $9.00 to $34.00. On average, they expect Valeant Pharmaceuticals' share price to reach $20.9231 in the next twelve months. This suggests that the stock has a possible downside of 10.6%. View Analyst Price Targets for Valeant Pharmaceuticals.

What is the consensus analysts' recommendation for Valeant Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeant Pharmaceuticals in the last year. There are currently 4 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Valeant Pharmaceuticals.

What are Wall Street analysts saying about Valeant Pharmaceuticals stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post a beat and raise quarter, we reiterating our OW rating and 12-month price target of C$32 for BHC shares. We think a greater appreciation for BHC’s solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+." (11/6/2018)
  • 2. HC Wainwright analysts commented, "Exchange NYSE Value (M) $31,421.0 Market Cap (M) $7,064 Public Market Float (M) 329.9 Shares Outstanding (M) 348.8 3 Interest (M) 40.90 Cash (M) $909.0 Total Debt (M) $25,266.0 Year – (0.25) FY 6.86 (7.48) (1.32) FY P/E 3.0x NM NM Year – 2,290.0 FY 8,724.0 8,325.0 8,810.0 30 25 20 15 10 0 Vol." (5/7/2018)
  • 3. According to Zacks Investment Research, "Valeant’s Bausch + Lomb/International segment and Salix businesses are doing well and should propel the top-line in the coming quarters. The approval of new drugs should boost the top line. After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Shares of the company have outperformed the industry in the last six months. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay lower debt is commendable. As of Feb 28, 2018, the company reduced total debt by approximately $6.7 billion since the end of first-quarter 2016. The dermatology business remains challenging and is expected to decline in 2018 as compared to 2017.  The guidance for 2018 was disappointing. Hence, it might be a while before the company turn arounds as management had projected." (4/2/2018)

Has Valeant Pharmaceuticals been receiving favorable news coverage?

Press coverage about VRX stock has been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Valeant Pharmaceuticals earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of Valeant Pharmaceuticals' key competitors?

Who are Valeant Pharmaceuticals' key executives?

Valeant Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
  • Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)

How do I buy shares of Valeant Pharmaceuticals?

Shares of VRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals' stock price today?

One share of VRX stock can currently be purchased for approximately $23.40.

What is Valeant Pharmaceuticals' official website?

The official website for Valeant Pharmaceuticals is http://www.valeant.com.

How can I contact Valeant Pharmaceuticals?

Valeant Pharmaceuticals' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The specialty pharmaceutical company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Valeant Pharmaceuticals (NYSE VRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,423 (Vote Outperform)
Underperform Votes:  1,197 (Vote Underperform)
Total Votes:  2,620
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel